The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI)
in young children is high. The RSV prevention strategies approved in 2023 will be essential …

Respiratory syncytial virus (RSV) stands as the foremost cause of infant hospitalization
globally, ranking second only to malaria in terms of infant mortality. Although three vaccines …

A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has
recently been licensed. We share our experiences of integrating nirsevimab into the regional …

Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory
infection in young children. RSV disease severity is known to be age-dependent and highest …

Respiratory syncytial virus (RSV) infections are a constant public health problem, especially
in infants and older adults. Virtually all children will have been infected with RSV by the age …

Background Respiratory syncytial virus (RSV) is a widespread respiratory pathogen, and
RSV-related acute lower respiratory tract infections are the most common cause of …

Soon after the discovery that respiratory syncytial virus (RSV) was the major cause of
bronchiolitis in infants, in 1956 [1], vaccines were developed to try and prevent both infection …

Whereas most infants infected with respiratory syncytial virus (RSV) show no or only mild
symptoms, an estimated 3 million children under five are hospitalized annually due to RSV …

Respiratory syncytial virus (RSV) has been recognized as a highly important cause of
morbidity and mortality among children and adults. A cross-sectional study at representative …

1. BACKGROUND The coronavirus disease 2019 (COVID‐19) pandemic has put immense
pressure on health care systems worldwide. Common symptoms of COVID‐19 include fever …